

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

**A mouse model of Bardet-Biedl Syndrome has impaired fear memory, which is rescued by lithium treatment**

Thomas K. Pak<sup>\*1,2,3,16</sup>, Calvin S. Carter<sup>\*3</sup>, Qihong Zhang<sup>3</sup>, Sunny C. Huang<sup>1,3</sup>, Charles Searby<sup>3</sup>, Ying Hsu<sup>3</sup>, Rebecca Taugher<sup>4,5</sup>, Tim Vogel<sup>3</sup>, Christopher C. Cychosz<sup>6</sup>, Rachel Genova<sup>1</sup>, Nina Moreira<sup>8</sup>, Hanna Stevens<sup>2,4</sup>, John Wemmie<sup>2,4,5,7</sup>, Andrew A. Pieper<sup>9-14</sup>, Kai Wang<sup>15</sup>, Val C. Sheffield<sup>2,3</sup>

1 Medical Scientist Training Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

2 Neuroscience Program, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

3 Department of Pediatrics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

4 Department of Psychiatry, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

5 Department of Veterans Affairs Medical Center, Iowa City, IA, USA

6 Department of Orthopedics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

7 Department of Molecular Physiology and Biophysics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

8 Department of Obstetrics and Gynecology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA

9 Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

10 Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA

11 Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center; Cleveland, OH, USA

27 12 Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve  
28 University, Cleveland, OH, USA

29 13 Weill Cornell Autism Research Program, Weill Cornell Medicine of Cornell University, NY, USA

30 14 Department of Neuroscience, Case Western Reserve University, School of Medicine, Cleveland, OH,  
31 USA

32 15 Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA

33 16 Corresponding author, Thomas-pak@uiowa.edu

34 \*These authors contributed equally to this work

35

36

37 **Data Availability:** All relevant data are within the paper and its Supporting Information files. Additional  
38 data that support the findings of this study are available from the corresponding author upon reasonable  
39 request.

40

41 **Competing interests:** The authors have declared that no competing interests exist.

42

43 **Funding:** This work was supported by NIH grants RO1 EY011298 and R01 EY017168 (to V.C.S.), and  
44 the Roy J. Carver Charitable Trust (V.C.S.). The work was also supported and greatly facilitated by the  
45 core facilities funded by NIH grant P30 EY025580 (PI: V.C.S.). AAP was supported by the Brockman  
46 Foundation, the Elizabeth Ring Mather & William Gwinn Mather Fund, S. Livingston Samuel Mather  
47 Trust, G.R. Lincoln Family Foundation, Wick Foundation, the Leonard Krieger Fund of the Cleveland  
48 Foundation, Gordon & Evie Safran, the Louis Stokes VA Medical Center resources and facilities, project  
49 19PABH134580006-AHA/Allen Initiative in Brain Health and Cognitive Impairment, NIH-NIA  
50 RO1AG066707 and the Translational Therapeutics Core of the Cleveland Alzheimer's Disease Research  
51 Center (NIH/NIA: 1 P30 AGO62428-01).

52

53 **Abstract**

54  
55 Primary cilia are microtubule-based organelles present on most cells that regulate many physiological  
56 processes, ranging from maintaining energy homeostasis to renal function. However, the role of these  
57 structures in the regulation of behavior remains unknown. To study the role of cilia in behavior, we  
58 employ mouse models of the human ciliopathy, Bardet-Biedl Syndrome (BBS). Here, we demonstrate  
59 that BBS mice have significant impairments in context fear conditioning, a form of associative learning.  
60 Moreover, we show that postnatal deletion of BBS gene function, as well as congenital deletion,  
61 specifically in the forebrain, impairs context fear conditioning. Analyses indicated that these behavioral  
62 impairments are not the result of impaired hippocampal long-term potentiation. However, our results  
63 indicate that these behavioral impairments are linked to impaired hippocampal neurogenesis. Two-week  
64 treatment with lithium chloride partially restores the proliferation of hippocampal neurons which leads to  
65 a rescue of context fear conditioning. Overall, our results identify a novel role of cilia genes in  
66 hippocampal neurogenesis and long-term context fear conditioning.

67  
68 **Author summary**

69  
70 The primary cilium is a microtubule-based membranous projection on the cell that is involved in multiple  
71 physiological functions. Patients who have cilia dysfunction commonly have intellectual disability.  
72 However, it is not known how cilia affect learning and memory. Studying mouse models of a cilia-based  
73 intellectual disability can provide insight into learning and memory. One such cilia-based intellectual  
74 disability is Bardet-Biedl Syndrome (BBS), which is caused by homozygous and compound heterozygous  
75 mutations of BBS genes. We found that a mouse model of BBS (*Bbs1*<sup>M390R/M390R</sup> mice) has learning and  
76 memory defects. In addition, we found that other mouse models of BBS have similar learning and  
77 memory defects. These BBS mouse models have difficulty associating an environment with an aversive

78 stimulus, a task designed to test context fear memory. This type of memory involves the hippocampus.  
79 We found that *Bbs1*<sup>M390R/M390R</sup> mice have decreased cell production in the hippocampus. Treating  
80 *Bbs1*<sup>M390R/M390R</sup> mice with a compound (lithium) that increases cell production in the hippocampus  
81 improved the learning and memory deficits. Our results demonstrate a potential role for cilia in learning  
82 and memory, and indicate that lithium is a potential treatment, requiring further study, for the intellectual  
83 disability phenotype of BBS.  
84

85 **Introduction**

86

87 Intellectual disability (ID) is one of the most common neurodevelopmental disorders, affecting 1% of the  
88 global population [1, 2]. Clinically, ID is characterized by a deficit in intellectual functioning and  
89 adaptive functioning [3]. There are limited pharmacological interventions for ID, partially due to the  
90 heterogeneous nature of ID, and a poor understanding of ID which can be attributed to a lack of animal  
91 models of ID [4, 5]. There is an urgent need to develop animal models to improve our understanding of  
92 the pathophysiological mechanisms underlying this pervasive condition.

93

94 Patients with abnormal cilia, i.e. ciliopathies, frequently present with ID, suggesting that cilia play an  
95 important role in learning and memory, yet the mechanisms underlying the phenotype remain unknown  
96 [6]. Primary cilia are microtubule-based structures that extend from the surface of nearly all cells in the  
97 body, including neurons. Cilia play a role in maintaining energy homeostasis and facilitating  
98 physiological responses to sensory stimuli [7]. There are robust mouse models of ciliopathies that  
99 recapitulate the primary features of the human ciliopathies, which allow us to study the role of cilia in  
100 learning and memory. To this end, we employed mouse models of the human ciliopathy, Bardet-Biedl  
101 Syndrome (BBS), which presents clinically with intellectual disability [8] in order to investigate the role  
102 of cilia in learning and memory.

103

104 BBS is a genetically heterogenous autosomal recessive ciliopathy with 22 known causative genes [9].  
105 Clinical features of BBS include rod-cone dystrophy progressing to blindness, postaxial polydactyly,  
106 obesity, renal anomalies, and intellectual disability [10]. BBS proteins are involved in ciliary function.  
107 Eight BBS genes, specifically *BBS1*, *BBS2*, *BBS4*, *BBS5*, *BBS7*, *BBS8*, *BBS9*, and *BBS18* (*BBIP1*),  
108 encode the components of the BBSome [11, 12], an octameric protein complex. The BBSome regulates  
109 ciliary trafficking of G-Protein Coupled Receptors (GPCR) including SMO[13], NPY2R [14], MCHR1  
110 and SSTR3[15], and D1R [16]), as well as non-GPCRs (TRKB[17]). Three non-BBSome BBS proteins

111 (BBS6, BBS10, and BBS12) form a complex that mediates the assembly of the BBSome [18]. BBS3 is a  
112 GTPase that is also involved in ciliary receptor trafficking[19].

113  
114 We have developed multiple mouse models of BBS [20]. Unlike some other ciliopathy mouse models,  
115 BBS models are viable and clinically relevant because they use mutations found in human patients [21-  
116 24]. We focused on the use of *Bbs1*<sup>M390R/M390R</sup> mice, harboring the most common human BBS mutation, as  
117 it recapitulates many of BBS phenotypes present in patients, including obesity, retinopathy, and decreased  
118 hippocampal volume[24, 25]. Despite the phenotypic association between decreased hippocampal volume  
119 in patients and the known role of the hippocampus in learning and memory, the role of BBS in learning  
120 and memory is not well studied. Here, we investigate the role of these cilia genes in learning and memory  
121 using a fear conditioning paradigm.

122  
123 Fear conditioning evaluates associative learning and involves pairing a neutral stimulus [conditioned  
124 stimulus (CS)], to an aversive stimulus [unconditioned stimulus (US)]. Fear conditioning is commonly  
125 used to understand the neurobiological mechanisms of ID as well as fear learning and memory in mice  
126 due to several advantages [26-29] . First, fear conditioning paradigms provide distinct insights into the  
127 neural correlates of learning and memory, for example, context or cue-dependent conditioning, which  
128 require contributions from different brain regions [30]. Second, the pairing of CS to US consistently  
129 elicits a measurable set of physiological and behavioral responses [31]. Third, fear conditioning allows for  
130 the delineation between short-term and long-term memory performance, depending on the time duration  
131 from training to testing. To assess short-term context fear conditioning, a one-hour interval between  
132 training and testing is utilized. To evaluate long-term context fear conditioning, an interval  $\geq 24$  hours is  
133 utilized [32-34]. Finally, fear conditioning is a form of passive learning, making it an accessible  
134 behavioral test for mice with motor deficits [35].

135

136 Here, we report that *Bbs1*<sup>M390R/M390R</sup> mice have impaired long-term context fear conditioning, but normal  
137 short-term context memory. In addition, we show that multiple BBS mouse models have impaired long-  
138 term context fear conditioning, including a mouse model with preferential deletion of *Bbs1* in the  
139 forebrain. We also show a novel role for BBS genes in neural proliferation and neurogenesis in the  
140 hippocampus. In addition, we show that two-week treatment with lithium chloride rescues long-term  
141 context fear conditioning and partially rescues hippocampal neurogenesis in *Bbs1*<sup>M390R/M390R</sup> mice.  
142 Overall, this study shows a molecular connection between primary cilia and learning and memory using  
143 mouse models of BBS. Our study also identifies lithium as a potential therapeutic agent for treating the  
144 intellectual disability aspect of BBS.

145

## 146 Results

147

### 148 1. *Bbs1*<sup>M390R/M390R</sup> mice have impaired long-term fear conditioning.

149

150 To study role of BBS in learning and memory, we employed a mouse model of the most common human  
151 BBS mutation, *Bbs1*<sup>M390R/M390R</sup>. Learning was evaluated using a three-day delay fear conditioning  
152 paradigm, which tests for long term association memory (Fig 1A). Controls were littermate heterozygote  
153 or wild-type mice as there is no difference in fear conditioning between these animals (S1 Fig). On day 1,  
154 both *Bbs1*<sup>M390R/M390R</sup> mice and their littermate controls showed increased freezing behavior following a  
155 shock stimulus, indicating that BBS mice exhibit a normal physiological response to an aversive stimulus  
156 (Fig 1B). On day 2 (post 24 hours from training), mice were introduced into a novel environment to test  
157 cue (sound) dependent fear conditioning. We found no significant differences between *Bbs1*<sup>M390R/M390R</sup> and  
158 control mice, indicating that BBS mice have intact cue dependent learning (Fig 1C). On day 3 (post 48  
159 hours from training), mice were re-introduced back into the training environment to test context  
160 (environment) dependent learning. Remarkably, *Bbs1*<sup>M390R/M390R</sup> mice showed a 28% reduction in freeze  
161 behavior in this environment relative to littermate controls (Fig 1C). A sex difference was not observed in  
162 control mice or *Bbs1*<sup>M390R/M390R</sup> mice for acquisition (immediate fear conditioning), cue fear conditioning  
163 (24 hours after acquisition), and context fear conditioning (48 hours after acquisition) (S2 Fig). These  
164 findings revealed that BBS mice have context specific fear conditioning impairments.

165

166 Due to the pleiotropic nature of BBS, we tested for confounding factors that may underlie the striking  
167 impairments in fear conditioning observed in *Bbs1*<sup>M390R/M390R</sup> mice. No hearing differences were observed  
168 between *Bbs1*<sup>M390R/M390R</sup> mice and control mice based on Auditory Brainstem Response and hearing  
169 behavior (S3A and S3B Fig). No differences were observed in shock reactivity between *Bbs1*<sup>M390R/M390R</sup>  
170 mice and control mice indicating a normal tactile response (S3C Fig). Moreover, we did not observe a



171 difference in activity levels or sleep behavior between *Bbs1*<sup>M390R/M390R</sup> mice and control mice (S3D and  
172 S3E Fig). These findings revealed that the impaired fear response is not due to a secondary effect of these  
173 sensory systems.

174

## 175 **2. *Bbs1*<sup>M390R/M390R</sup> mice have normal short-term fear conditioning.**

176

177 We tested short-term fear conditioning in BBS mice to assess if the long-term memory deficit is due to  
178 short-term memory impairment. To test for short-term fear conditioning, we used a 1-day fear  
179 conditioning paradigm (Fig 2A). Both the control mice (*Bbs1*<sup>M390R/+</sup> mice) and *Bbs1*<sup>M390R/M390R</sup> mice  
180 showed intact conditioning to shock (Fig 2B). In addition, there was no significant difference in short-  
181 term context memory between the control mice and *Bbs1*<sup>M390R/M390R</sup> mice (Fig 2C). These results are in  
182 contrast to the differences in long-term context memory, which showed impaired performance in  
183 *Bbs1*<sup>M390R/M390R</sup> mice compared to controls (Fig 1C). These findings indicated that BBS mice have specific  
184 impairments in long-term context fear conditioning.

185

## 186 **3. Mice with postnatal deletion of *Bbs8* have impaired long-term context fear conditioning**

187

188 We took advantage of another BBS mouse model to further explore the role of BBS genes (especially  
189 BBSome genes) in fear conditioning, specifically a tamoxifen inducible knock-out mouse model of BBS8  
190 [36]. BBS8, like BBS1, is a component of the BBSome [11]. Using *Bbs8* tamoxifen inducible knock-out  
191 mice, we evaluated the temporal effects of BBS8 on fear conditioning (Fig 3A). For controls, we used  
192 littermates lacking *Cre*. Tamoxifen was administered to both groups of mice to control for possible effects  
193 of tamoxifen on behavior [37]. Following day 1 of fear conditioning, mice with *Bbs8* postnatally deleted,  
194 as well as control mice, were successfully conditioned to fear (Fig 3B). However, significant impairments  
195 in context but not cue fear conditioning were observed between conditional KO *Bbs8* mice and controls

196 (Fig 3C). These results are similar to the results for *Bbs1*<sup>M390R/M390R</sup> mice, indicating a role of the BBSome  
197 in mediating long-term context fear conditioning. Although, we observed differences in the acquisition  
198 curve of day 1 fear conditioning between conditional KO *Bbs8* mice and controls, no difference was  
199 found in immediate fear conditioning (Fig 3B and 3C). These results indicate that like *Bbs1*, *Bbs8* is  
200 involved in long-term context fear conditioning.

201

#### 202 **4. Mice with preferential deletion of *Bbs1* in the forebrain have impaired long-term context** 203 **fear conditioning**

204

205 The forebrain contains brain regions involved in fear conditioning including the amygdala and  
206 hippocampus[30]. To explore whether the absence of normal BBS1 function in the forebrain is  
207 responsible for the fear conditioning impairment observed in *Bbs1*<sup>M390R/M390R</sup> mice, we utilized a forebrain-  
208 specific *Bbs1* knock-out mouse line developed by crossing a *Bbs1*<sup>fllox/fllox</sup> conditional mouse line with a *Cre*  
209 line expressed in the forebrain (*Emx1-Cre* mice). The *Emx1-Cre* mice were generated and verified by  
210 Gorski et al. [38]. Using an Ai9 Cre reporter allele, we confirmed that the Cre is preferentially expressed  
211 in the forebrain (S4A and S4B Fig). We also confirmed that *Bbs1* is excised in the forebrain, but  
212 unexcised in the hindbrain of *Bbs1*<sup>fllox/fllox</sup>, *Emx1-Cre*<sup>+</sup> mice (S4C Fig), further confirming the specificity of  
213 *Cre* expression in *Emx1-Cre* mice.

214

215 Control mice (*Emx1-Cre*, *Bbs1*<sup>+/+</sup> mice) and forebrain specific *Bbs1* knockout mice (*Emx1-Cre*; *Bbs1*<sup>fllox/-</sup>  
216 mice) were fear conditioned using a three-day fear conditioning paradigm (Fig 4A). Acquisition of  
217 conditioning to shock was intact for both control mice and forebrain specific *Bbs1* knockout mice (Fig  
218 4B). However, forebrain specific *Bbs1* knockout mice showed impaired context fear conditioning  
219 compared to controls (Fig 4C). Cue fear conditioning was observed to be intact for both knockout and  
220 control mice. These results indicate that BBS1 in the forebrain is required for contextual memory.

221

222 **5. *Bbs1*<sup>M390R/M390R</sup> mice do not have impaired long-term potentiation**

223

224 Since *Bbs1*<sup>M390R/M390R</sup> mice have impaired context fear conditioning, which is hippocampus dependent  
225 [30], we investigated hippocampal function in *Bbs1*<sup>M390R/M390R</sup> mice. We evaluated long-term potentiation  
226 (LTP) in the CA1 region of the hippocampus because LTP is a neural correlate for long-term memory  
227 consolidation [39]. In addition, some mouse models with impaired context fear conditioning have  
228 impaired long-term potentiation (LTP) in CA1 of the hippocampus [32, 40, 41]. Despite the important  
229 role of LTP in fear conditioning, we did not observe a difference in LTP between control mice and  
230 *Bbs1*<sup>M390R/M390R</sup> mice in CA1 of the hippocampus (Fig 5A and 5B). These results suggest that the observed  
231 impaired learning arises from causes other than impaired LTP.

232

233 **6. *Bbs1*<sup>M390R/M390R</sup> mice have decreased hippocampal neurogenesis**

234

235 Next, we sought to identify a potential cause of the defective long-term fear conditioning observed in  
236 BBS mice, It has been recently reported that BBS patients have decreased hippocampal volume which is  
237 thought to be a result of impaired neurogenesis [42]. Due to the known role that cilia play in mediating  
238 cell proliferation and hippocampal volume in patients [43, 44], we hypothesized that defective  
239 hippocampal neurogenesis underlies the fear conditioning deficits in BBS mice. Therefore, we  
240 investigated hippocampal neurogenesis in *Bbs1*<sup>M390R/M390R</sup> mice.

241

242 To measure proliferation, we injected *Bbs1*<sup>M390R/M390R</sup> mice and control mice with BrdU, a thymidine  
243 analog that is incorporated into replicating DNA to label proliferating cells (Fig 5C and 5E). Following  
244 BrdU labeling, we found that both neonatal (P3) and young adult (P44) *Bbs1*<sup>M390R/M390R</sup> mice displayed  
245 significant reductions in BrdU+ cells in the hippocampal dentate gyrus compared to controls (Fig 5D, Fig

246 5F-5H). Moreover, young adult *Bbs1*<sup>M390R/M390R</sup> mice also showed fewer new neurons as determined by a  
247 reduced number of cells co-labeled for BrdU and Doublecortin, a marker for immature neurons (Fig 6B  
248 and 6D) [45].

249  
250 The role of the observed impairments in hippocampal neurogenesis in long-term context fear conditioning  
251 of *Bbs1*<sup>M390R/M390R</sup> is unclear. To test the role of neurogenesis, we utilized a pharmacological modality to  
252 enhance hippocampal neurogenesis. Because impaired neurogenesis within the dentate gyrus is associated  
253 with long term memory deficits, we reasoned that rescue of impaired neurogenesis could improve fear  
254 conditioning impairments. To this end, we chose lithium due to its previous use as an agent to improve  
255 neurogenesis and hippocampal dependent memory [46-48].

256  
257 We began by assessing the effects of lithium on hippocampal neurogenesis in *Bbs1*<sup>M390R/M390R</sup> mice and  
258 control mice. Young adult mice were treated with lithium or vehicle (water) for two weeks, and then brain  
259 tissues were harvested and stained for BrdU and Doublecortin (Fig 6A and 6B). Compared to vehicle  
260 treated mice, lithium treatment led to a 153% increase in the number of new neurons in the dentate gyrus  
261 of the hippocampus (Fig 6C and 6D).

262

263

## 264 **7. Lithium treatment rescued long-term context fear conditioning in *Bbs1*<sup>M390R/M390R</sup> mice**

265

266 We hypothesized that enhancing hippocampal neurogenesis using lithium treatment would rescue context  
267 which is hippocampus dependent [30]. To test the effects of lithium on fear conditioning, 4-5 week old  
268 mice were administered lithium or vehicle for two weeks (Fig 6E). The mice underwent fear conditioning  
269 using the three-day paradigm (Fig 6E-6G). As hypothesized, lithium treatment rescued the long-term  
270 context fear conditioning, but not long-term cue fear conditioning for *Bbs1*<sup>M390R/M390R</sup> mice (Fig 6G).

271 Taken together, these observations suggest BBS genes play an important role in mediating hippocampal  
272 neurogenesis and long-term context fear conditioning.

273

274 **Discussion:**

275

276 Intellectual disability (ID) is the most common neurodevelopmental disorder [1]. ID has limited  
277 pharmacological treatments, which is attributed to a limited understanding of the mechanisms involved. A  
278 large reason for the lack of mechanistic understanding is due to a lack of mouse models with ID as a  
279 primary phenotype. To overcome this hurdle, we explored the use of mouse models of the human  
280 disorder, Bardet-Biedl Syndrome (BBS) for the study of ID.

281

282 We showed that BBS mice have impaired context fear conditioning, indicating that BBS genes play a  
283 critical role in long-term memory. Our studies elucidated the spatial and temporal role of BBS gene  
284 function in fear memory. Using a conditional *Bbs1* knock-out mouse model, we demonstrated that BBS1  
285 in the forebrain plays an important role in long-term fear memory. These findings are consistent with  
286 prior reports that cilia in the forebrain are involved in long-term fear memory[49]. In addition, the use of a  
287 novel tamoxifen inducible *Bbs8* knock-out mouse model demonstrated that BBS gene function is also  
288 critical during the post-natal consolidation of long-term fear memory.

289

290 Our work is in contrast to previous work using BBS mice to study their role in fear conditioning, which  
291 gave inconsistent results [50, 51]. This is partially explained by the use of different mouse strains and  
292 testing parameters. This previous work used *Bbs4* null mice on C57BL/6 [51] or FVB/NJ[50]  
293 backgrounds. In addition, these studies have noted a sex difference in BBS mice (*Bbs4* knock-out mice)  
294 with respect to fear conditioning, which we do not observe [51]. The discrepancies in findings may be due  
295 to differences in mouse strains or study design. Our study primarily used strains 129/SvEv and C57BL/6.  
296 We used a strong learning paradigm with five pairings of shocks, compared to three shock pairings[51] or  
297 two shock pairings[50]. BBS4 mice were evaluated in the previous study compared to BBS1M390R and  
298 BBS8 knock-out mice in the current study. Although BBS4, BBS1 and BBS8 are all components of the  
299 BBSome, it is possible that these proteins could have unique properties on fear memory.

300  
301 Since BBS is a pleiotropic disorder, there are other factors that could explain the context fear conditioning  
302 impairment observed in mouse models of BBS. The *Bbs1*<sup>M390R/M390R</sup> mice have visual deficits [24],  
303 olfactory deficits [52], obesity [24] and hydrocephalus, which could globally affect fear conditioning. In  
304 order to control for these phenotypes, we used young adult mice prior to the onset of obesity and  
305 blindness. In addition, our BBS1 conditional knock-out mice are not blind nor obese and BBS8  
306 conditional knock-out mice do not have hydrocephalus [19, 53], yet both models have impaired long-term  
307 context fear conditioning. We are not able to account for the olfactory deficit as a confounding factor.  
308 However, if these phenotypes underlie the observed fear conditioning deficits, *Bbs1*<sup>M390R/M390R</sup> mice would  
309 also display short-term (immediate) fear conditioning deficits in addition to long-term deficits, which we  
310 did not observe. Therefore, we conclude that the fear learning deficits observed are a primary phenotype  
311 due to the absence of BBS gene function.

312  
313 Other mouse models demonstrate fear memory deficits similar to those we report in this study. For  
314 example, long-term context fear conditioning, but not short-term context fear conditioning, has been  
315 reported in mice with absent neuronal nitric oxide synthase [34], mice with inhibited protein synthesis  
316 [33], and in mice with PKA [32, 33] or MAP Kinase deficiencies [33]. While these mouse models have  
317 impaired long-term potentiation (LTP) in CA1 of the hippocampus, there are mouse models with  
318 impaired memory that have normal LTP [49, 54] as is the case with our *Bbs1*<sup>M390R/M390R</sup> mice.

319  
320 The decreased hippocampal neurogenesis in *Bbs1*<sup>M390R/M390R</sup> mice is a novel finding that can explain the  
321 impaired fear context memory. Hippocampal neurogenesis is involved in hippocampus dependent  
322 learning, such as context fear conditioning. Impaired context fear conditioning has been reported in mice  
323 with genetic suppression of proliferation of GFAP expressing cells [55, 56] and Nestin expressing cells  
324 [57, 58]. Impaired fear context long-term memory has also been reported in mice with suppressed

325 hippocampal neurogenesis through irradiation of the head [59] and ganciclovir treated mice [55],  
326 supporting our results using BBS mouse models.

327

328 We speculate that BBS proteins affect hippocampal neurogenesis because BBS is involved in ciliary  
329 receptor trafficking of the Smoothed Receptor [13, 60, 61], which is involved in SHH signaling.  
330 SHH signaling is mediated by primary cilia [43]. Primary cilia are particularly enriched in the  
331 hippocampus [62]. Furthermore, SHH signaling has a proliferative effect on adult hippocampal  
332 progenitors *in vitro and in vivo* [63]. In addition, both primary cilia and smoothed receptors (hedgehog  
333 signaling) are required by adult neural stem cells [64]. The role of BBS in hippocampal proliferation may  
334 also be due to their involvement in tyrosine receptor kinase B (TrkB) receptor signaling [17]. Brain  
335 derived neurotrophic factor (BDNF) has been shown to increase neurogenesis through TrkB receptors  
336 [65, 66].

337

338 We investigated lithium as a treatment for the memory and neural deficits of *Bbs1*<sup>M390R/M390R</sup> mice.  
339 Lithium has been shown to improve learning and memory tasks in mouse models of cognitive disease  
340 including Fragile X syndrome[67], Down syndrome[48], and Alzheimer disease[46]. In addition, lithium  
341 treatment affects the morphology of primary cilia in the brain[68] and lithium has also been shown to  
342 increase hippocampal neurogenesis [46, 48, 69]. While lithium treatment of *Bbs1*<sup>M390R/M390R</sup> mice  
343 produced a robust effect on memory performance, lithium treatment produced a more modest response in  
344 hippocampal proliferation and neurogenesis. This suggests that a modest change in hippocampal  
345 proliferation and neurogenesis can produce a profound effect on memory. Consistent with these findings,  
346 a Danish study shows a correlation between lower incidence of dementia and long-term exposure to  
347 lithium in drinking water[70]. In addition, a study in China showed that low-dose lithium treatment  
348 improved cognitive performance in children with ID without major side effects[71]. Our results  
349 demonstrate the therapeutic potential of an FDA approved drug, lithium, for treating the cognitive and  
350 neural phenotypes of BBS patients.



351  
352 It is possible that lithium has other neural effects contributing to the rescue of context fear conditioning.  
353 For example, lithium has been reported to alter dendritic spine density in the hippocampus [72] and to  
354 improve olfaction in mouse models of olfactory impairment [73, 74].  
355  
356 Further research is needed to explore factors involved in decreased hippocampal neurogenesis in  
357 *Bbs1*<sup>M390R/M390R</sup> mice. In our young adult mouse study, we observed a decrease in the number of  
358 BrdU+/Doublecortin+ cells in the hippocampus, indicating decreased neurogenesis. However, the  
359 apparent decrease in neurogenesis could be due to decreased proliferation, decreased differentiation  
360 and/or decreased. Any of these factors could be likely because BBS proteins are involved in the function  
361 of primary cilia, and primary cilia are involved in proliferation, differentiation [75] and survival[76].  
362  
363 There are alternative explanations for the cause of the impaired learning and memory in BBS mouse  
364 models. BBS proteins traffic other ciliary receptors that are involved in learning and memory. *Bbs4*  
365 knock-out mice [16] and *Bbs7* knock-out mice [77] accumulate dopamine 1 (D1) receptors in cilia. D1  
366 receptors are involved in learning and memory[78, 79]. BBS proteins are also involved in trafficking of  
367 the somatostatin receptor 3 (SSTR3) [60] and melanin concentrating hormone receptor 1 (MCHR1) [15],  
368 both of which are involved in learning and memory [80, 81].  
369  
370 Our mouse model of a ciliopathy with ID robustly presented with impaired fear memory in context fear  
371 conditioning and decreased neurogenesis. In addition, our mouse model of BBS presented similarly to the  
372 mouse model of Fragile X Syndrome[82]. Fragile X syndrome is one of the most commonly inherited  
373 disorders for intellectual disability [83], and has recently been found to have defective cilia [84]. Overall,  
374 the findings presented here support the use of BBS mice as a model for ID and support the use of pro-  
375 neurogenic treatments as a possible treatment for ID.

376



378 **Methods**

379

380 **Study Approval:**

381

382 This research was conducted in strict accordance to the Guide for the Care and Use of Laboratory  
383 Animals, 8<sup>th</sup> edition, from the National Research Council. All mice were handled based on approved  
384 Institutional Animal Care and Use Committee (IACUC) protocols (#5061426 and #8072147) at the  
385 University of Iowa. Animals were housed in facilities, maintained by the Office of Animal Resources that  
386 adhere to IACUC recommendations. Mice were euthanized either by anesthesia induced by I.P injection  
387 of ketamine/xylazine followed by transcardiac perfusion, or carbon dioxide inhalation followed by  
388 cervical dislocation. Every effort was made to minimize suffering in the mice, and humane endpoints  
389 were stringently observed.

390

391 **Animals**

392

393 All mice were group housed on a set 12 hr light-dark cycle and given standard chow (LM-485; Teklab,  
394 Madison, WI, USA) and water ad libitum. Mice were generated at the University of Iowa Carver College  
395 of Medicine and all experiments were performed in accordance with the Institute for Animal Care and  
396 Use Committee at the University of Iowa. For all testing, we used young adult mice (1.5-3 month old  
397 mice), unless otherwise noted. The ages of mice were chosen to keep the weight and visual processing  
398 differences between *Bbs1*<sup>M390R/M390R</sup> and control mice to a minimal [24]. All testing was conducted during  
399 the light cycle, unless otherwise noted.

400

401 We used several strains of mice as listed below. Control mice were of the same genetic strains as the mice  
402 with which they were compared. We used male and female mice on a pure 129/SvEv genetic background  
403 for *Bbs1*<sup>M390R/M390R</sup> mice and littermate controls (*Bbs1*<sup>+/+</sup> and *Bbs1*<sup>M390R/+</sup>). Heterozygote mice (*Bbs1*<sup>M390R/+</sup>)

404 do not exhibit BBS phenotypes [24, 47], and are not significantly different in fear conditioning compared  
405 to *Bbs1*<sup>+/+</sup> mice. To generate mice with preferential *Bbs1* deletion in the forebrain, we crossed *Bbs1*<sup>flox/flox</sup>  
406 mice (129/SvEv) [47] with *Emx1-Cre* knock-in mice (C57BL/6) (Jackson Laboratory, #005628). To  
407 verify forebrain *Cre* expression, we crossed *Emx1-Cre* knock-in mice with the Ai9 *Cre* reporter line  
408 *Gt(ROSA)26Sor*<sup>tm9(CAG-tdTomato)Hze</sup> (C57BL/6) (Jackson Laboratory #007909). We also used conditional  
409 *Bbs8* knock-out mice (*Bbs8*<sup>flox/flox</sup>, C57BL/6) [36] crossed with tamoxifen-inducible *Cre* recombinase  
410 mice, B6.Cg-*Ndori1*<sup>Tg(UBC-cre/ERT2)1Ejb</sup>/2J (Jackson Laboratory #008085).

411

412

### 413 **Tamoxifen-inducible excision of *Bbs8***

414

415 We postnatally excised *Bbs8* according to previously described procedures [36]. To induce *Cre*  
416 expression, *Bbs8*<sup>flox/flox</sup> and *Bbs8*<sup>flox/-</sup>; *UBC-Cre*<sup>ERT2</sup><sup>+</sup> mice were injected subcutaneously with 40  $\mu$ L of  
417 tamoxifen (15 mg/mL in corn oil) on three separate days (P9, P12, and P15). *Bbs8*<sup>flox/flox</sup> and *Bbs8*<sup>flox/-</sup>;  
418 *UBC-Cre*<sup>ERT2</sup><sup>-</sup> mice injected with tamoxifen were the littermate controls. We assessed excision efficiency  
419 as previously described [36]. The *Bbs8* tamoxifen inducible knock-out mice (*Bbs8*<sup>flox/flox</sup> and *Bbs8*<sup>flox/-</sup>;  
420 *UBC-Cre*<sup>ERT2</sup><sup>+</sup>) that were determined to have less than 90% excision were excluded from the research  
421 study. This was decided as an exclusion criterion prior to conducting the study. No other mice were  
422 excluded from the research study.

423

424

### 425 **Behavioral Testing**

426

427 All behavioral testing was conducted during the light cycle, unless otherwise noted.

428

429 Delay Fear Conditioning: For fear conditioning, mice were placed in a fear conditioning chamber with  
430 near-infrared video. Freezing was scored with the VideoFreeze software (Med Associates, St. Albans,  
431 VT, USA). Fear conditioning can distinguish short-term context memory from long-term context memory  
432 based on when context fear conditioning is tested (short-term is 1 hour after conditioning, and long-term  
433 is  $\geq 24$  hours after conditioning) [32-34]. A 3-day protocol was used to assess both long-term cue and  
434 contextual fear conditioning.

435 • On the first day of fear conditioning, a 20-second tone (75 dB) was played, which co-terminated  
436 with a 1-second foot shock (0.75 mA). The tone-shock pairings occurred five times, with the  
437 shocks at 3:20m, 5:40m, 8m, 10:20m and 12:40m. For the acquisition curve figure, the freezing  
438 data was reported as the percent time the mouse was immobile for each one-minute bout. In  
439 addition, the training in day 1 fear conditioning was measured as:

440 ○ Immediate fear conditioning = freezing time (%) just after conditioning (last minute) - the  
441 freezing time (%) just before conditioning (first three minutes)

442 • On the second day, to test cue fear conditioning, mice were tested in a novel context in which  
443 floor texture, odor, and shape of the chamber had been altered. After 3 minutes in the chamber, a  
444 3-minute tone (75 dB) was delivered, followed by an additional 4 minutes without the tone.

445 The cue fear conditioning was measured as:

446 ○ Cue fear conditioning = freezing time (%) during the tone on day 2 – freezing time (%)  
447 before the tone on day 2

448 • On the third day, to test contextual fear conditioning, the chamber was set back to the original  
449 training context. Mice were placed in the chamber for 5 minutes. The context fear conditioning  
450 was measured as:

451 ○ Context fear conditioning = freezing time (%) on day 3 - freezing time (%) just before  
452 conditioning (first three minutes of day 1).

453

454 One day fear conditioning: The acquisition protocol for three-day fear conditioning was used for the one  
455 day fear conditioning protocol. After the acquisition phase, mice were placed back into their home cage.  
456 One hour after the fear conditioning, mice were placed back into the original training chamber, and  
457 recorded for five minutes. The short-term context fear conditioning was measured as the difference of the  
458 freezing time (%) just before conditioning (first three minutes of day 1) and during the context on day 1  
459 (one hour after fear conditioning).

460

461 Preyer Reflex: The Preyer reflex is the startle response to auditory stimuli. Mice were given an auditory  
462 stimulus (hand clap) in their home cage. A positive sign was noted if the mouse had a rapid movement of  
463 the whole body after the auditory stimulus.

464

465 Circling Behavior: Circling behavior is noted in animal models of deafness [85]. Mice were observed for  
466 5 minutes in their home cage for circling behavior. A positive circling behavior was noted if the mouse  
467 tightly circled around itself more than two times.

468

### 469 **Auditory Brainstem Response**

470

471 The auditory brainstem response (ABR) test provides information about the auditory sensitivity of the  
472 subject. The ABR test was conducted on 2-month old control mice (n=3) and *Bbs1*<sup>M390R/M390R</sup> mice (n=4).

473 The experimenter was masked to the genotype. The ABR test were conducted as previously described  
474 [86]. Briefly, clicks and tone-bursts were delivered to the testing ear through a plastic acoustic tube in a  
475 sound attenuated room. ABRs were measured using an Etymotic Research ER10B+ probe microphone  
476 (Etymotic Research, Elk Grove, IL, USA) coupled to two Tucker-Davis Technologies MF1 multi-field  
477 magnetic speakers (Tucker-Davis Technologies, Alachua, FL, USA). Click and tone-burst stimuli were  
478 presented and recorded using custom software running on a PC connected to a 24-bit external sound card  
479 (Motu UltraLite mk3, Cambridge MA, USA). A custom-built differential amplifier with a gain of 1,000

480 dB amplified acoustic ABR responses. Output was passed through 6-pole Butterworth high-pass (100 Hz)  
481 and low-pass (3 kHz) filters and then to a 16-bit analog-to-digital converter (100,000 sample/s). The tone  
482 bursts were 3 ms in length, in addition to 1 ms onset and offset ramps (raised cosine shape) centered at 4,  
483 8, 16, 24, and 32 kHz. Responses were recorded using standard signal-averaging techniques for 500 or  
484 1000 sweeps. Hearing thresholds (db SPL) were determined by decreasing the sound intensity by 5 and/or  
485 10 db decrements and recording the lowest sound intensity level resulting in a recognizable and  
486 reproducible ABR response wave pattern. Maximum ABR thresholds were capped at 100 db SPL.

487

### 488 **BrdU injections**

489

490 For early postnatal time points, mice were injected intraperitoneally with 300mg/kg Bromodeoxyuridine  
491 (BrdU, Sigma, St. Louis, Missouri) and sacrificed 4 hours after the injection. For later postnatal time  
492 points, mice were injected intraperitoneally with 50mg/kg BrdU twice a day for five days, and sacrificed  
493 ten days later.

494

### 495 **Lithium Treatment**

496

497 We treated mice with 45mmol lithium chloride (Sigma) in drinking water starting at four to five weeks of  
498 age for 2 weeks. Mice were group-housed for lithium treatment and group-housed for vehicle (water)  
499 treatment. Littermate controls were group-housed.

500

501

### 502 **Tissue collections and histology**

503

504 For early postnatal tissue, fresh brain tissues were collected and embedded in Optimal Cutting  
505 Temperature compound (OCT, Tissue Tek, Sakura Finetek). Eight  $\mu\text{m}$  sections were cut on a cryostat.

506 For late postnatal time points, mice were anesthetized by intraperitoneal injection of Ketamine (17.5  
507 mg/cc)/Xylazine (2.5 mg/cc) at 100  $\mu$ L/20 gram body weight, and transcardially perfused with 4%  
508 paraformaldehyde in phosphate-buffered saline (PBS). The brain and eyes were removed and post-fixed  
509 overnight at 4°C with 4% paraformaldehyde in PBS, followed by more than 24 hours of immersion in  
510 30% sucrose in PBS. Tissues were then embedded in OCT (Tissue Tek, Sakura Finetek). 20  $\mu$ m sections  
511 were cut on a cryostat.

512

513

#### 514 **Immunohistochemistry**

515

516 Tissue sections were directly placed on positively charged microscope slides (Globe Scientific). Tissue  
517 sections were fluorescently immunostained for the following markers: anti-tdtomato: 1:500 rabbit  
518 polyclonal anti-DsRed (Living Colors), immature neuronal marker anti-Doublecortin (1:500, abcam)  
519 proliferative marker anti-BrdU (1:200, Abcam). The AlexaFluor tagged secondary antibodies used were  
520 Alexa488 (green), Alexa568 (red), and Alexa633 (far red) (Molecular Probes). Antigen retrieval was  
521 used for neuronal markers (50 mMol Tris HCl, 45 minutes at 80 °C) and BrdU marker (2N HCl, 0.1%  
522 triton, 30 minutes in 37°C)

523

524 In preparation for staining, slides with sections were placed in 50 mM Tris HCl for 45 minutes at 80°C.  
525 After slides were cooled, slides were incubated in 2N HCl (0.1% Triton) at 37°C for 30 minutes and  
526 rinsed in 0.1 M boric acid (pH 8.5) at room temperature for 10 minutes. Sections were then rinsed in  
527 PBST (0.2% Triton X-100/ PBS), blocked for one hour with block solution (2% bovine serum in  
528 PBS/0.1% Triton X-100), and incubated overnight with anti-BrdU antibody and anti-Hu antibody in  
529 serum solution (1% bovine serum in PBS/0.1% Triton X-100) at 4°C. Sections were washed in PBST,  
530 incubated with secondary antibodies in serum solution at RT for 2 hours, washed in PBST, counterstained  
531 with DAPI, and cover slipped with Vectashield© antifade mounting medium (Vector Laboratories).



532

### 533 **Cell quantification**

534

535 Tissue sections used for BrdU quantification were imaged using an inverted fluorescent microscope  
536 (Olympus IX71). Exposure was kept constant for each channel within experiments. Four to six  
537 representative dentate gyri from coronal sections were counted per mouse subject. The number of BrdU+  
538 cells were counted within the dentate gyrus of a 20x image (Figure 3C). BrdU is a marker for proliferating  
539 cells. The BrdU+ cell counts were standardized to the volume of dentate gyrus tissue in the image (mm<sup>3</sup>).  
540 Volume was determined by measuring the area of the dentate gyrus on ImageJ and multiplying the area  
541 by the thickness of the tissue. For analysis of neurogenesis, Doublecortin+BrdU+ and BrdU+ cell within  
542 the dentate gyrus were counted. Doublecortin is a marker for immature neurons [45]. The tissue sections  
543 used for quantification were imaged using confocal microscopy (SP8 confocal microscope, Leica). To  
544 determine the frequency of BrdU+ cells expressing DCX, dual fluorescence-labeled sections were  
545 examined by confocal microscopy using a 20x objective (Figure 3F, S6). Sections were scored for single  
546 or double labeling by manual examination of optical slices. Cells were manually counted for double  
547 labeling when DCX labeling was unambiguously associated with a BrdU+ nucleus. Cells were spot-  
548 checked in all three dimensions by Z-stack using a 20x objective. In all cases, the observer was masked to  
549 the treatment and genotypes.

550

### 551 **Comprehensive Lab Animal Monitoring System**

552

553 For analysis of whole animal activity levels and sleep behavior, *Bbs1*<sup>M390R/M390R</sup> mice (n=7) and control  
554 mice (n=9) were placed in a Comprehensive Lab Animal Monitoring System (CLAMS; Columbus  
555 Instruments, Columbus, OH, USA). CLAMS is an open circuit system that directly measures various  
556 parameters over a 72 hour period including movement, sleep behavior, food intake, VO<sub>2</sub>, VCO<sub>2</sub>, and heat  
557 production. Mice were weighed before the CLAMS recording. Mice were individually housed in

558 Plexiglas cage chambers that were kept at 24°C under a 12:12 hour light-dark cycle. The chamber had 0.6  
559 liters of air passed per minute. Movement (activity) was measured by XY laser beam interruption, and  
560 sleep behavior was measured as minimum movement for four minutes or longer. Food consumption was  
561 monitored by electronic scales. For measuring the O<sub>2</sub> and CO<sub>2</sub>, the gas content of the exhaust air from  
562 each chamber was compared with the gas content of the ambient air sample. The V̇O<sub>2</sub> and V̇CO<sub>2</sub>  
563 measurements were normalized to mouse body weight. The following parameters were calculated as  
564 followed: RER = V̇CO<sub>2</sub>/V̇O<sub>2</sub>, heat production = 1.232\*V̇CO<sub>2</sub>+3.815\*V̇O<sub>2</sub>. CLAMS were performed  
565 at the University of Iowa Fraternal Order of Eagles Diabetes Research Center Metabolic Phenotyping  
566 Core.

567

#### 568 **Slice preparation and electrophysiology**

569 Hippocampal slices from group-housed, naive 2-months old *Bbs1*<sup>M390R/M390R</sup> mice (n=4) and control mice  
570 (n=4) were prepared as previously described [87]. First, tissue brain blocks were affixed to the cutting  
571 stage, submerged in cutting solution, and transversely sectioned at 400 μm on a Vibratome 1000 Plus  
572 (Vibratome, St. Louis, MO). After bisecting into hemispheres, slices were transferred to a holding  
573 chamber containing artificial cerebrospinal fluid (aCSF). After 30 minutes, the holding chamber was  
574 removed from the water bath and held at RT (22°C) for the remainder of the experiment.

575

576 To record field excitatory post-synaptic potentials (fEPSP), aCSF-filled borosilicate electrodes (Corning  
577 #0010 glass, resistance <1 MΩ) were positioned in the stratum radiatum of area CA1. Synaptic responses  
578 were evoked by stimulation of Schaffer collaterals with bipolar tungsten electrodes (0.1 MΩ, parylene  
579 coated; World Precision Instruments, Sarasota, FL). Signals were amplified (AxoClamp 900A Amplifier,  
580 Axon Instruments, Foster City, CA), filtered at 1 kHz, digitally-sampled at 10 kHz (Axon Digidata 1440),  
581 and stored for offline analysis in Clampfit 10 (Molecular Devices, San Jose, CA).

582

583 An input-output curve (initial slope of fEPSP plotted against stimulus intensity) for assessment of basal  
584 synaptic transmission was first generated by delivering pulses of 0.2 ms duration every 15 s at increasing  
585 stimulation intensities to elicit synaptic responses. Stimulation intensity was then adjusted to yield 40 -  
586 60% of the maximal fEPSP amplitude. The input/output curve is primarily used to calibrate the setting for  
587 LTP of the tissue, along with assessing the viability of the tissue.

588  
589 After acquiring stable baseline responses for 15 minutes, LTP was induced by a theta-burst stimulation  
590 protocol consisting of 12 bursts of 4 pulses at 100 Hz. Synaptic responses were sampled every 15 s for 1 h  
591 after induction. For analysis, the initial slope of each fEPSP was normalized to the average baseline slope.  
592 Time-matched, normalized slopes were then averaged among slices from animals of the same genotype  
593 for comparison and plotted as an average of four consecutive responses (*i.e.*, responses sampled over 1  
594 minute). Slices with maximal fEPSPs of less than 0.5 mV, disproportionately large fiber volleys,  
595 substantial changes in fiber volley amplitude during LTP recordings, or unstable synaptic responses  
596 during baseline or LTP recordings were excluded.

597

#### 598 **Statistical Analysis:**

599 Statistical analyses were performed using GraphPad Prism 8.0 (GraphPad Software, San Diego, CA). For  
600 comparison of two groups, we ran a two-tailed Welch's t-test. The Welch's t-test is recommended over  
601 the Student t-test because Welch's t-test performs better when the sample sizes and variances are unequal  
602 between groups, and gives similar results when sample sizes and variances are equal [88, 89]. Preliminary  
603 tests of equality of variances to determine t-tests are not recommended since it impairs the validity of the  
604 Welch's t-test [90]. For data that appear skewed, we also ran a Mann-Whitney-Wilcoxon Test. For  
605 multiple comparisons, we ran multiple t-tests (analyzed each row individually and did not assume  
606 consistent standard deviations) corrected for multiple comparisons using the Holm-Sidak method. A two-  
607 way ANOVA was used for comparisons of multiple groups with two different independent variables. We  
608 then ran a Sidak post-hoc analysis for the relevant data. A three-way ANOVA was used for comparison of

609 multiple groups with three different independent variables. Graphs were generated on GraphPad Prism  
610 8.0. Data are presented as mean with the error bars indicating standard error of means (unless otherwise  
611 noted).

612

613

#### 614 **Author Contributions**

615

616 Conceived and designed the experiments: TP, CSC, RT, AP, JW, VCS, HS, and QZ. Performed the  
617 experiments: TP, TV, CSC, CS, YH, CCC, and RG. Analyzed the data: TP, CSC, SCH, NM, CCC, RG,  
618 RT, VCS, and KW. Contributed reagents/materials/analysis tools: CSC, SCH, NM, YH, AP, and JW.  
619 Wrote the paper: TP, CSC, HS, QZ, RT, JW and VCS.

620

#### 621 **Acknowledgements**

622

623 We thank Valerie Bouffard and Janelle Garrison for the animal husbandry and genotyping. We thank  
624 Chantal Allamargot and Kathy Walters, in the Central Microscopy Research Facility at the University of  
625 Iowa, for technical assistance in microscopy. We thank Paul Ranum and Richard Smith for their technical  
626 assistance with the Auditory Brainstem Response. We want to acknowledge Jamie Soto of the Metabolic  
627 Phenotype Core at the University of Iowa, for her technical help with CLAMS. We thank Hamza Farooq  
628 for drawing Figure 1a. We thank AJ Chowdhury for assisting with editing of the manuscript. We would  
629 also like to acknowledge Denise Harder for her administrative support.

630

631

632 **References**

- 633 1. Bavley CC, Rice RC, Fischer DK, Fakira AK, Byrne M, Kosovsky M, et al. Rescue of Learning  
634 and Memory Deficits in the Human Nonsyndromic Intellectual Disability Cereblon Knock-Out Mouse  
635 Model by Targeting the AMP-Activated Protein Kinase–mTORC1 Translational Pathway. *The Journal of*  
636 *Neuroscience*. 2018;38(11):2780-95.
- 637 2. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual  
638 disability: A meta-analysis of population-based studies. *Research in Developmental Disabilities*.  
639 2011;32(2):419-36.
- 640 3. von Wilamowitz-Moellendorff A, Hunter RW, García-Rocha M, Kang L, López-Soldado I,  
641 Lantier L, et al. Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in  
642 hepatic glycogen synthesis. *Diabetes*. 2013;62(12):4070-82. Epub 2013/08/29.
- 643 4. Picker JD, Walsh CA. New innovations: therapeutic opportunities for intellectual disabilities.  
644 *Annals of neurology*. 2013;74(3):382-90. Epub 2013/09/17.
- 645 5. Scorza CA, Cavalheiro EA. Animal models of intellectual disability: towards a translational  
646 approach. *Clinics (Sao Paulo, Brazil)*. 2011;66 Suppl 1(Suppl 1):55-63.
- 647 6. Park SM, Jang HJ, Lee JH. Roles of Primary Cilia in the Developing Brain. *Frontiers in Cellular*  
648 *Neuroscience*. 2019;13(218).
- 649 7. Oh EC, Vasanth S, Katsanis N. Metabolic regulation and energy homeostasis through the primary  
650 Cilium. *Cell metabolism*. 2015;21(1):21-31. Epub 12/24.
- 651 8. Beales PL, Elcioglu N, Woolf AS, Parker D, Flintner FA. New criteria for improved diagnosis of  
652 Bardet-Biedl syndrome: results of a population survey. *Journal of medical genetics*. 1999;36(6):437-46.  
653 Epub 2000/06/30.
- 654 9. Forsythe E, Beales PL. Bardet-Biedl syndrome. *European journal of human genetics : EJHG*.  
655 2013;21(1):8-13.
- 656 10. Sheffield V, Zhang Q, Heon E, drack AV, Stone AEL, Carmi R. Epstein's Inborn Errors of  
657 Development: The Molecular Basis of Clinical Disorders of Morphogenesis: Oxford University Press;  
658 2016.
- 659 11. Nachury MV, Loktev AV, Zhang Q, Westlake CJ, Peranen J, Merdes A, et al. A core complex of  
660 BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. *Cell*.  
661 2007;129(6):1201-13. Epub 2007/06/19.
- 662 12. Loktev AV, Zhang Q, Beck JS, Searby CC, Scheetz TE, Bazan JF, et al. A BBSome subunit links  
663 ciliogenesis, microtubule stability, and acetylation. *Dev Cell*. 2008;15(6):854-65. Epub 2008/12/17.
- 664 13. Zhang Q, Seo S, Bugge K, Stone EM, Sheffield VC. BBS proteins interact genetically with the  
665 IFT pathway to influence SHH-related phenotypes. *Human Molecular Genetics*. 2012;21(9):1945-53.
- 666 14. Loktev Alexander V, Jackson Peter K. Neuropeptide Y Family Receptors Traffic via the Bardet-  
667 Biedl Syndrome Pathway to Signal in Neuronal Primary Cilia. *Cell Reports*. 2013;5(5):1316-29.
- 668 15. Berbari NF, Lewis JS, Bishop GA, Askwith CC, Mykytyn K. Bardet-Biedl syndrome proteins are  
669 required for the localization of G protein-coupled receptors to primary cilia. *Proc Natl Acad Sci USA*.  
670 2008;105.
- 671 16. Domire JS, Green JA, Lee KG, Johnson AD, Askwith CC, Mykytyn K. Dopamine receptor 1  
672 localizes to neuronal cilia in a dynamic process that requires the Bardet-Biedl syndrome proteins. *Cellular*  
673 *and molecular life sciences : CMLS*. 2011;68(17):2951-60. Epub 2010/12/15.
- 674 17. Leitch CC, Zaghoul NA. BBS4 Is Necessary for Ciliary Localization of TrkB Receptor and  
675 Activation by BDNF. *PLOS ONE*. 2014;9(5):e98687.
- 676 18. Seo S, Baye LM, Schulz NP, Beck JS, Zhang Q, Slusarski DC, et al. BBS6, BBS10, and BBS12  
677 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. *Proceedings of the*  
678 *National Academy of Sciences*. 2010;107(4):1488-93.
- 679 19. Zhang Q, Nishimura D, Seo S, Vogel T, Morgan DA, Searby C, et al. Bardet-Biedl syndrome 3  
680 (Bbs3) knockout mouse model reveals common BBS-associated phenotypes and Bbs3 unique

- 681 phenotypes. *Proceedings of the National Academy of Sciences of the United States of America*.  
682 2011;108(51):20678-83. Epub 2011/12/06.
- 683 20. Wehbrecht K, Goar WA, Pak T, Garrison JE, DeLuca AP, Stone EM, et al. Keeping an Eye on  
684 Bardet-Biedl Syndrome: A Comprehensive Review of the Role of Bardet-Biedl Syndrome Genes in the  
685 Eye. *Medical research archives*. 2017;5(9):10.18103/mra.v5i9.1526.
- 686 21. Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L, Anderson KV. Hedgehog signalling  
687 in the mouse requires intraflagellar transport proteins. *Nature*. 2003;426.
- 688 22. Liu A, Wang B, Niswander LA. Mouse intraflagellar transport proteins regulate both the activator  
689 and repressor functions of Gli transcription factors. *Development (Cambridge, England)*. 2005;132.
- 690 23. Cortellino S, Wang C, Wang B, Bassi MR, Caretti E, Champeval D, et al. Defective ciliogenesis,  
691 embryonic lethality and severe impairment of the Sonic Hedgehog pathway caused by inactivation of the  
692 mouse complex A intraflagellar transport gene *Ift122/Wdr10*, partially overlapping with the DNA repair  
693 gene *Med1/Mbd4*. *Developmental biology*. 2009;325(1):225-37. Epub 10/29.
- 694 24. Davis RE, Swiderski RE, Rahmouni K, Nishimura DY, Mullins RF, Agassandian K, et al. A  
695 knockin mouse model of the Bardet-Biedl syndrome 1 M390R mutation has cilia defects,  
696 ventriculomegaly, retinopathy, and obesity. *Proceedings of the National Academy of Sciences of the  
697 United States of America*. 2007;104(49):19422-7. Epub 2007/11/23.
- 698 25. Baker K, Northam GB, Chong WK, Banks T, Beales P, Baldeweg T. Neocortical and  
699 hippocampal volume loss in a human ciliopathy: A quantitative MRI study in Bardet-Biedl syndrome.  
700 *American Journal of Medical Genetics Part A*. 2011;155(1):1-8.
- 701 26. Crawley JN. *What's Wrong With My Mouse?: Behavioral Phenotyping of Transgenic and  
702 Knockout Mice*: John Wiley & Sons, Inc.; 2006. Available from:  
703 <https://onlinelibrary.wiley.com/doi/book/10.1002/0470119055>.
- 704 27. Murru L, Vezzoli E, Longatti A, Ponzoni L, Falqui A, Folci A, et al. Pharmacological Modulation  
705 of AMPAR Rescues Intellectual Disability-Like Phenotype in *Tm4sf2*<sup>-/-</sup> Mice. *Cerebral cortex (New  
706 York, NY : 1991)*. 2017;27(11):5369-84. Epub 2017/10/03.
- 707 28. Rajadhyaksha AM, Ra S, Kishinevsky S, Lee AS, Romanienko P, DuBoff M, et al. Behavioral  
708 characterization of cereblon forebrain-specific conditional null mice: A model for human non-syndromic  
709 intellectual disability. *Behavioural brain research*. 2012;226(2):428-34.
- 710 29. Matzel LD, Han YR, Grossman H, Karnik MS, Patel D, Scott N, et al. Individual Differences in  
711 the Expression of a "General" Learning Ability in Mice. *The Journal of Neuroscience*. 2003;23(16):6423-  
712 33.
- 713 30. Phillips RG, LeDoux JE. Differential contribution of amygdala and hippocampus to cued and  
714 contextual fear conditioning. *Behavioral neuroscience*. 1992;106(2):274-85. Epub 1992/04/01.
- 715 31. Johansen Joshua P, Cain Christopher K, Ostroff Linnaea E, LeDoux Joseph E. Molecular  
716 Mechanisms of Fear Learning and Memory. *Cell*. 2011;147(3):509-24.
- 717 32. Abel T, Nguyen PV, Barad M, Deuel TA, Kandel ER, Bourtchouladze R. Genetic demonstration  
718 of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. *Cell*.  
719 1997;88(5):615-26. Epub 1997/03/07.
- 720 33. Schafe GE, Atkins CM, Swank MW, Bauer EP, Sweatt JD, LeDoux JE. Activation of ERK/MAP  
721 Kinase in the Amygdala Is Required for Memory Consolidation of Pavlovian Fear Conditioning. *The  
722 Journal of Neuroscience*. 2000;20(21):8177-87.
- 723 34. Kelley JB, Balda MA, Anderson KL, Itzhak Y. Impairments in fear conditioning in mice lacking  
724 the nNOS gene. *Learning & memory (Cold Spring Harbor, NY)*. 2009;16(6):371-8.
- 725 35. Curzon P, Rustay N, Browman K. *Methods of Behavior Analysis in Neuroscience*. Boca Raton  
726 (FL): CRC Press/Taylor & Francis; 2009. Available from:  
727 <https://www.ncbi.nlm.nih.gov/books/NBK5223/>.
- 728 36. Hsu Y, Garrison JE, Kim G, Schmitz AR, Searby CC, Zhang Q, et al. BBSome function is  
729 required for both the morphogenesis and maintenance of the photoreceptor outer segment. *PLoS genetics*.  
730 2017;13(10):e1007057.

- 731 37. Li X, Du ZJ, Chen MQ, Chen JJ, Liang ZM, Ding XT, et al. The effects of tamoxifen on mouse  
732 behavior. *Genes Brain Behav.* 2020;19(4):e12620. Epub 2019/10/28.
- 733 38. Gorski JA, Talley T, Qiu M, Puelles L, Rubenstein JLR, Jones KR. Cortical Excitatory Neurons  
734 and Glia, But Not GABAergic Neurons, Are Produced in the Emx1-Expressing Lineage. *The Journal of*  
735 *Neuroscience.* 2002;22(15):6309-14.
- 736 39. Cooke SF, Bliss TVP. Plasticity in the human central nervous system. *Brain : a journal of*  
737 *neurology.* 2006;129(7):1659-73.
- 738 40. Bourtchuladze R, Frenguelli B, Blendy J, Cioffi D, Schutz G, Silva AJ. Deficient long-term  
739 memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. *Cell.*  
740 1994;79(1):59-68.
- 741 41. Xie C-W, Sayah D, Chen Q-S, Wei W-Z, Smith D, Liu X. Deficient long-term memory and long-  
742 lasting long-term potentiation in mice with a targeted deletion of neurotrophin-4 gene. *Proceedings of the*  
743 *National Academy of Sciences.* 2000;97(14):8116-21.
- 744 42. Baker K, Northam GB, Chong WK, Banks T, Beales P, Baldeweg T. Neocortical and  
745 hippocampal volume loss in a human ciliopathy: A quantitative MRI study in Bardet-Biedl syndrome.  
746 *American journal of medical genetics Part A.* 2011;155a(1):1-8. Epub 2011/01/05.
- 747 43. Breunig JJ, Sarkisian MR, Arellano JI, Morozov YM, Ayoub AE, Sojitra S, et al. Primary cilia  
748 regulate hippocampal neurogenesis by mediating sonic hedgehog signaling. *Proceedings of the National*  
749 *Academy of Sciences of the United States of America.* 2008;105(35):13127-32. Epub 2008/08/30.
- 750 44. Amador-Arjona A, Elliott J, Miller A, Ginbey A, Pazour GJ, Enikolopov G, et al. Primary Cilia  
751 Regulate Proliferation of Amplifying Progenitors in Adult Hippocampus: Implications for Learning and  
752 Memory. *The Journal of Neuroscience.* 2011;31(27):9933-44.
- 753 45. Brown JP, Couillard-Després S, Cooper-Kuhn CM, Winkler J, Aigner L, Kuhn HG. Transient  
754 expression of doublecortin during adult neurogenesis. *The Journal of comparative neurology.*  
755 2003;467(1):1-10. Epub 2003/10/24.
- 756 46. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F. Lithium Improves Hippocampal  
757 Neurogenesis, Neuropathology and Cognitive Functions in APP Mutant Mice. *PLOS ONE.*  
758 2010;5(12):e14382.
- 759 47. Carter CS, Vogel TW, Zhang Q, Seo S, Swiderski RE, Moninger TO, et al. Abnormal  
760 development of NG2+PDGFR- $\alpha$ + neural progenitor cells leads to neonatal hydrocephalus in a ciliopathy  
761 mouse model. *Nature Medicine.* 2012;18:1797.
- 762 48. Bianchi P, Ciani E, Contestabile A, Guidi S, Bartesaghi R. Lithium Restores Neurogenesis in the  
763 Subventricular Zone of the Ts65Dn Mouse, a Model for Down Syndrome. *Brain Pathology.*  
764 2010;20(1):106-18.
- 765 49. Barbari NF, Malarkey EB, Yazdi SM, McNair AD, Kippe JM, Croyle MJ, et al. Hippocampal and  
766 cortical primary cilia are required for aversive memory in mice. *PLoS One.* 2014;9(9):e106576. Epub  
767 2014/09/04.
- 768 50. Eichers ER, Abd-El-Barr MM, Paylor R, Lewis RA, Bi W, Lin X, et al. Phenotypic  
769 characterization of Bbs4 null mice reveals age-dependent penetrance and variable expressivity. *Hum*  
770 *Genet.* 2006;120(2):211-26.
- 771 51. Haq N, Schmidt-Hieber C, Sialana FJ, Ciani L, Heller JP, Stewart M, et al. Loss of Bardet-Biedl  
772 syndrome proteins causes synaptic aberrations in principal neurons. *PLOS Biology.*  
773 2019;17(9):e3000414.
- 774 52. Williams CL, Uyttingco CR, Green WW, McIntyre JC, Ukhanov K, Zimmerman AD, et al. Gene  
775 Therapeutic Reversal of Peripheral Olfactory Impairment in Bardet-Biedl Syndrome. *Molecular therapy :*  
776 *the journal of the American Society of Gene Therapy.* 2017;25(4):904-16. Epub 02/22.
- 777 53. Singh M, Garrison JE, Wang K, Sheffield VC. Absence of BBSome function leads to astrocyte  
778 reactivity in the brain. *Molecular brain.* 2019;12(1):48-.
- 779 54. Fragkouli A, Hearn C, Errington M, Cooke S, Grigoriou M, Bliss T, et al. Loss of forebrain  
780 cholinergic neurons and impairment in spatial learning and memory in LHX7-deficient mice. *The*  
781 *European journal of neuroscience.* 2005;21(11):2923-38. Epub 2005/06/28.

- 782 55. Saxe MD, Battaglia F, Wang J-W, Malleret G, David DJ, Monckton JE, et al. Ablation of  
783 hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate  
784 gyrus. *Proceedings of the National Academy of Sciences*. 2006;103(46):17501-6.
- 785 56. Denny CA, Burghardt NS, Schachter DM, Hen R, Drew MR. 4- to 6-week-old adult-born  
786 hippocampal neurons influence novelty-evoked exploration and contextual fear conditioning.  
787 *Hippocampus*. 2012;22(5):1188-201. Epub 2011/07/09.
- 788 57. Imayoshi I, Sakamoto M, Ohtsuka T, Takao K, Miyakawa T, Yamaguchi M, et al. Roles of  
789 continuous neurogenesis in the structural and functional integrity of the adult forebrain. *Nature*  
790 *neuroscience*. 2008;11(10):1153-61. Epub 2008/09/02.
- 791 58. Deng W, Saxe MD, Gallina IS, Gage FH. Adult-born hippocampal dentate granule cells  
792 undergoing maturation modulate learning and memory in the brain. *The Journal of neuroscience : the*  
793 *official journal of the Society for Neuroscience*. 2009;29(43):13532-42. Epub 2009/10/30.
- 794 59. Winocur G, Wojtowicz JM, Sekeres M, Snyder JS, Wang S. Inhibition of neurogenesis interferes  
795 with hippocampus-dependent memory function. *Hippocampus*. 2006;16(3):296-304. Epub 2006/01/18.
- 796 60. Ye F, Nager AR, Nachury MV. BBSome trains remove activated GPCRs from cilia by enabling  
797 passage through the transition zone. *The Journal of Cell Biology*. 2018.
- 798 61. Nozaki S, Katoh Y, Kobayashi T, Nakayama K. BBS1 is involved in retrograde trafficking of  
799 ciliary GPCRs in the context of the BBSome complex. *PLoS ONE*. 2018;13(3):e0195005.
- 800 62. Bishop GA, Berbari NF, Lewis J, Mykytyn K. Type III adenylyl cyclase localizes to primary cilia  
801 throughout the adult mouse brain. *The Journal of comparative neurology*. 2007;505(5):562-71. Epub  
802 2007/10/11.
- 803 63. Lai K, Kaspar BK, Gage FH, Schaffer DV. Sonic hedgehog regulates adult neural progenitor  
804 proliferation in vitro and in vivo. *Nature neuroscience*. 2003;6(1):21-7. Epub 2002/12/07.
- 805 64. Han YG, Spassky N, Romaguera-Ros M, Garcia-Verdugo JM, Aguilar A, Schneider-Maunoury  
806 S, et al. Hedgehog signaling and primary cilia are required for the formation of adult neural stem cells.  
807 *Nature neuroscience*. 2008;11(3):277-84. Epub 2008/02/26.
- 808 65. Li Y, Luikart BW, Birnbaum S, Chen J, Kwon CH, Kerner SG, et al. TrkB regulates hippocampal  
809 neurogenesis and governs sensitivity to antidepressive treatment. *Neuron*. 2008;59(3):399-412. Epub  
810 2008/08/15.
- 811 66. Islam O, Loo TX, Heese K. Brain-derived neurotrophic factor (BDNF) has proliferative effects  
812 on neural stem cells through the truncated TRK-B receptor, MAP kinase, AKT, and STAT-3 signaling  
813 pathways. *Current neurovascular research*. 2009;6(1):42-53. Epub 2009/04/10.
- 814 67. King MK, Jope RS. Lithium treatment alleviates impaired cognition in a mouse model of fragile  
815 X syndrome. *Genes, Brain and Behavior*. 2013;12(7):723-31.
- 816 68. Miyoshi K, Kasahara K, Miyazaki I, Asanuma M. Lithium treatment elongates primary cilia in  
817 the mouse brain and in cultured cells. *Biochem Biophys Res Commun*. 2009;388(4):757-62. Epub  
818 2009/08/26.
- 819 69. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal  
820 neurogenesis by lithium. *Journal of neurochemistry*. 2000;75(4):1729-34. Epub 2000/09/15.
- 821 70. Kessing LV, Gerds TA, Knudsen NN, Jørgensen LF, Kristiansen SM, Voutchkova D, et al.  
822 Association of Lithium in Drinking Water With the Incidence of Dementia. *JAMA Psychiatry*.  
823 2017;74(10):1005-10.
- 824 71. Yuan J, Song J, Zhu D, Sun E, Xia L, Zhang X, et al. Lithium Treatment Is Safe in Children With  
825 Intellectual Disability. *Frontiers in molecular neuroscience*. 2018;11:425-.
- 826 72. Shim SS, Hammonds MD, Mervis RF. Four weeks lithium treatment alters neuronal dendrites in  
827 the rat hippocampus. *International Journal of Neuropsychopharmacology*. 2013;16(6):1373-82.
- 828 73. Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD. Lithium and valproate  
829 prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-  
830 1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. *Behavioural brain research*.  
831 2012;229(1):208-15. Epub 2012/01/24.



- 832 74. Guidi S, Bianchi P, Stagni F, Giacomini A, Emili M, Trazzi S, et al. Lithium Restores Age-  
833 related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome. *CNS & neurological*  
834 *disorders drug targets*. 2017;16(7):812-9. Epub 2016/08/05.
- 835 75. Irigoien F, Badano JL. Keeping the balance between proliferation and differentiation: the primary  
836 cilium. *Current genomics*. 2011;12(4):285-97.
- 837 76. Bowie E, Goetz SC. TTBK2 and primary cilia are essential for the connectivity and survival of  
838 cerebellar Purkinje neurons. *eLife*. 2020;9:e51166.
- 839 77. Zhang Q, Nishimura D, Vogel T, Shao J, Swiderski R, Yin T, et al. BBS7 is required for  
840 BBSome formation and its absence in mice results in Bardet-Biedl syndrome phenotypes and selective  
841 abnormalities in membrane protein trafficking. *Journal of cell science*. 2013;126(11):2372-80.
- 842 78. El-Ghundi M, Fletcher PJ, Drago J, Sibley DR, O'Dowd BF, George SR. Spatial learning deficit  
843 in dopamine D(1) receptor knockout mice. *European journal of pharmacology*. 1999;383(2):95-106. Epub  
844 1999/12/11.
- 845 79. Sarinana J, Kitamura T, Kunzler P, Sultzman L, Tonegawa S. Differential roles of the dopamine  
846 1-class receptors, D1R and D5R, in hippocampal dependent memory. *Proceedings of the National*  
847 *Academy of Sciences of the United States of America*. 2014;111(22):8245-50. Epub 2014/05/21.
- 848 80. Einstein EB, Patterson CA, Hon BJ, Regan KA, Reddi J, Melnikoff DE, et al. Somatostatin  
849 signaling in neuronal cilia is critical for object recognition memory. *The Journal of neuroscience : the*  
850 *official journal of the Society for Neuroscience*. 2010;30(12):4306-14. Epub 2010/03/26.
- 851 81. Adamantidis A, Thomas E, Foidart A, Tyhon A, Coumans B, Minet A, et al. Disrupting the  
852 melanin-concentrating hormone receptor 1 in mice leads to cognitive deficits and alterations of NMDA  
853 receptor function. *The European journal of neuroscience*. 2005;21(10):2837-44. Epub 2005/06/02.
- 854 82. Guo W, Allan AM, Zong R, Zhang L, Johnson EB, Schaller EG, et al. Ablation of Fmrp in adult  
855 neural stem cells disrupts hippocampus-dependent learning. *Nature Medicine*. 2011;17(5):559-65.
- 856 83. Hersh JH, Saul RA. Health Supervision for Children With Fragile X Syndrome. *Pediatrics*.  
857 2011;127(5):994-1006.
- 858 84. Lee B, Panda S, Lee HY. Primary Ciliary Deficits in the Dentate Gyrus of Fragile X Syndrome.  
859 *Stem Cell Reports*. 2020;15(2):454-66.
- 860 85. Lee JW, Lee EJ, Hong SH, Chung WH, Lee HT, Lee TW, et al. Circling mouse: possible animal  
861 model for deafness. *Comparative medicine*. 2001;51(6):550-4. Epub 2002/04/02.
- 862 86. Soken H, Robinson BK, Goodman SS, Abbas PJ, Hansen MR, Kopelovich JC. Mouse  
863 cochleostomy: a minimally invasive dorsal approach for modeling cochlear implantation. *The*  
864 *Laryngoscope*. 2013;123(12):E109-15. Epub 2013/05/16.
- 865 87. Yin TC, Britt JK, De Jesus-Cortes H, Lu Y, Genova RM, Khan MZ, et al. P7C3 neuroprotective  
866 chemicals block axonal degeneration and preserve function after traumatic brain injury. *Cell reports*.  
867 2014;8(6):1731-40. Epub 2014/09/16.
- 868 88. Ruxton GD. The unequal variance t-test is an underused alternative to Student's t-test and the  
869 Mann-Whitney U test. *Behavioral Ecology*. 2006;17(4):688-90.
- 870 89. Delacre M, Lakens D, Leys C. Why Psychologists Should by Default Use Welch's t-test Instead  
871 of Student's t-test. *International Review of Social Psychology*. 2017;30(1):92-101.
- 872 90. Zimmerman DW. A note on preliminary tests of equality of variances. *The British journal of*  
873 *mathematical and statistical psychology*. 2004;57(Pt 1):173-81. Epub 2004/06/03.

874

875

876

877


878

# Figures

879

880

881



882

883 **Fig 1. *Bbs1*<sup>M390R/M390R</sup> mice have impaired long-term context fear conditioning.**


884 A.) Schematic diagram of the delay fear conditioning procedure. On the first day, a mouse was placed in a  
 885 chamber, and a sound was paired with a shock multiple times. On the second day, a mouse was placed in  
 886 an altered chamber. The chamber was triangle shaped (represented by the blue triangle) with a smooth  
 887 floor, and a sound was given to test long-term cue fear conditioning. On the third day, the mouse was  
 888 placed back in the same chamber (context) as day 1, without a sound cue. This set up was used to test  
 889 long-term context fear conditioning.

890 B.) Day 1 acquisition between the control mice (n=16) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=16) for long-term  
 891 fear conditioning differed significantly (2-way ANOVA, time X genotype, F (13, 420) = 0.4488, P=0.950,  
 892 time, F (13, 420) = 179.8, P<0.0001, genotype, F (1, 420) = 11.46, P=0.0008). The thick lines above the

893 curve indicate when the sound cue was given, and the thick lines below the curve indicate when the shock  
894 was given.

895 C.) The immediate fear conditioning indicates training to the day 1 fear conditioning. The immediate fear  
896 conditioning was measured as the difference of the freezing time (%) just before conditioning (first three  
897 minutes) and just after conditioning (last minute). The immediate fear conditioning did not differ  
898 significantly between the control mice (n=16) and *Bbs1*<sup>M390/M390R</sup> mice (n=16) used for long-term fear  
899 conditioning (Welch's t-test, P=0.2107). The post 24 hr fear conditioning represents cue fear  
900 conditioning, and is portrayed as Day 2 on the schematic diagram. The 24 hr fear conditioning (cue) was  
901 measured as the difference of the freezing time (%) before the tone (cue) on day 2 and during the tone  
902 (cue) on day 2. The 24 hr fear conditioning (cue) did not differ significantly between the control mice  
903 (n=16) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=16) (Welch's t-test, P=0.2414). The post 48 hr fear conditioning  
904 represents context fear conditioning, and is portrayed as Day 3 on the schematic diagram. The 48 hr fear  
905 conditioning was measured as the difference of the freezing time (%) just before conditioning (first three  
906 minutes of day 1) and during the context on day 3. The 48 hr fear conditioning (context) between the  
907 control mice (n=16) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=16) differed significantly (Welch's t-test, P=0.0240).  
908 control mice = *Bbs1*<sup>M390R/+</sup> mice, M390R = *Bbs1*<sup>M390R/M390R</sup> mice, hr = hour, ns = not significant \* P < 0.05,  
909 \*\* P < 0.01, \*\*\* P < 0.001 \*\*\*\* P < 0.0001

910



911

912 **Fig 2. *Bbs1*<sup>M390R/M390R</sup> mice have normal short-term context fear conditioning.**

913 A.) Schematic diagram of the one day delay fear conditioning procedure. On the first day, a mouse was  
914 placed in a chamber, and a sound was paired with a shock multiple time. One hour later, the mouse was  
915 placed back in the chamber, and freezing was measured for short-term context fear conditioning.


916 B.) Day 1 acquisition between the control mice (n=9) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=9) used for the short  
917 term fear conditioning differed significantly (2-way ANOVA, time X genotype, F (13, 224) = 0.5574 ,  
918 P=0.8858, time, F (13, 224) = 56.19, P<0.0001, genotype, F (1, 224) = 9.369, P=0.0025). The thick lines  
919 above the curve indicate when the sound cue was given, and the thick lines below the curve indicate when  
920 the shock was given.

921 C.) The immediate fear conditioning indicates training to the day 1 fear conditioning. The immediate fear  
922 conditioning was measured as the difference of the freezing time (%) just before conditioning (first three

923 minutes) and just after conditioning (last minute). The immediate fear conditioning did not differ  
924 significantly between control mice (n=9) and *Bbs1*<sup>M390/M390R</sup> mice (n=9) used for the short-term fear  
925 conditioning (Welch's t-test, P=0.8004). The 1 hr fear conditioning represents short-term context fear  
926 conditioning. The 1 hr fear conditioning was measured as the difference of the freezing time (%) just  
927 before conditioning and 1 hour after conditioning. The day 1 fear conditioning for context between the  
928 control mice (n=9) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=9) did not reveal a significant difference (Welch's t-  
929 test, P=0.3436).

930 control mice = *Bbs1*<sup>M390R/+</sup> mice, M390R = *Bbs1*<sup>M390R/M390R</sup> mice, hr = hour, ns = not significant \* P < 0.05,  
931 \*\* P < 0.01, \*\*\* P < 0.001, \*\*\*\* P < 0.0001

932



933

934 **Fig 3. Postnatal BBS genes are involved in long-term context fear conditioning.**

935 A.) Timeline of the tamoxifen I.P injections of the experimental mice, *Cre+* (*Bbs* $\delta^{\text{flox/-}}$  and *Bbs* $\delta^{\text{flox/flox}}$ ,  
 936 *UBC-Cre<sup>ERT2</sup>*) and littermate control mice, *Cre-* (*Bbs* $\delta^{\text{flox/-}}$  and *Bbs* $\delta^{\text{flox/flox}}$ ; *UBC-Cre<sup>ERT2</sup>-*). To induce  
 937 *Bbs* $\delta$  deletion in *Cre+* mice, Tamoxifen was injected at P9, P12, and P15 (denoted by the syringe image).  
 938 At 2 months of age, the mice were tested for long-term fear conditioning. The first day was the  
 939 acquisition phase for fear conditioning, the second day was cue fear conditioning, and the third day was  
 940 context fear conditioning.


941 B.) Day 1 acquisition curve between the *Cre-* mice (n=9) and *Cre+* mice (n=9) differed significantly (2-  
 942 way ANOVA, time X genotype,  $F(13, 224) = 1.721$ ,  $p = 0.0579$ , time,  $F(13, 224) = 31.71$ ,  $P < 0.0001$ ,  
 943 genotype,  $F(1, 224) = 39.16$ ,  $P < 0.0001$ ). The thick lines above the curve indicate when the sound cue  
 944 was given, and the thick lines below the curve indicate when the shock was given.

945 C.) The immediate fear conditioning indicates training to the day 1 fear conditioning. The immediate fear  
946 conditioning was measured as the difference of the freezing time (%) just before conditioning (first three  
947 minutes) and just after conditioning (last minute). The immediate fear conditioning did not differ  
948 significantly between the *Cre*<sup>-</sup> mice (n=9) and *Cre*<sup>+</sup> mice (n=9) used for long-term fear conditioning  
949 (Welch's t-test, P=0.3717). The post 24 hr fear conditioning represents cue fear conditioning, and is  
950 portrayed as Day 2 on the schematic diagram. The 24 hr fear conditioning (cue) was measured as the  
951 difference of the freezing time (%) before the tone (cue) on day 2 and during the tone (cue) on day 2. The  
952 24 hr fear conditioning (cue) did not differ significantly between the *Cre*<sup>-</sup> mice (n=9) and *Cre*<sup>+</sup> mice  
953 (n=9) (Welch's t-test, P=0.4325). The post 48 hr fear conditioning represents context fear conditioning,  
954 and is portrayed as Day 3 on the schematic diagram. The 48 hr fear conditioning was measured as the  
955 difference of the freezing time (%) just before conditioning (first three minutes of day 1) and during the  
956 context on day 3. The 48 hr fear conditioning (context) between the *Cre*<sup>-</sup> mice (n=9) and *Cre*<sup>+</sup> mice  
957 (n=9) differed significantly (Welch's t-test, P=0.0099).

958 *Cre*<sup>-</sup> = *Bbs* $\delta^{\text{floX/-}}$  and *Bbs* $\delta^{\text{floX/floX}}$ ; *UBC-Cre*<sup>ERT2</sup>- mice, *Cre*<sup>+</sup> = *Bbs* $\delta^{\text{floX/-}}$  and *Bbs* $\delta^{\text{floX/floX}}$ ; *UBC-Cre*<sup>ERT2</sup> +  
959 mice, hr = hour, del=deletion, flx= flox, hr=hour, ns =not significant \* P< 0.05, \*\* P< 0.01, \*\*\*P<0.001,  
960 \*\*\*\*P<0.0001

961





962

963 **Fig 4. BBS genes in the forebrain are involved in long-term context fear conditioning.**


964 A.) Schematic diagram of the three day delay fear conditioning procedure. On the first day, a mouse was  
 965 placed in a chamber, and a sound was paired with a shock multiple time. On the second day, a mouse was  
 966 placed in an altered chamber that was triangle shaped (represented by the blue triangle) with a smooth  
 967 floor, and a sound was given to measure cue fear conditioning. On the third day, the mouse was placed  
 968 back in the same chamber, and measured for freezing without sound. This gives the context fear  
 969 conditioning.

970 B.) Day 1 acquisition between the *Emx1-Cre* mice (control, mixed strain of C57BL/6 and 129/SVeV,  
 971 n=12) and the *Bbs1<sup>fllox/-</sup>; Emx1-Cre* (BBS1 CKO, mixed strain of C57BL/6 and 129/SVeV, n=13) differed  
 972 significantly (2-way ANOVA, time X genotype,  $F(13, 322) = 3.483, P < 0.0001$ , time,  $F(13, 322) =$

973 93.95,  $P < 0.0001$ , genotype,  $F(1, 322) = 137.5$ ,  $P < 0.0001$ ). The thick lines above the curve indicate when  
974 the sound cue was given, and the thick lines below the curve indicate when the shock was given.  
975 C.) The immediate fear conditioning indicates training to the day 1 fear conditioning. The immediate fear  
976 conditioning was measured as the difference of the freezing time (%) just before conditioning (first three  
977 minutes) and just after conditioning (last minute). The immediate fear conditioning did not differ  
978 significantly between the control *Emx1-Cre* mice ( $n=12$ ) and *Bbs1<sup>fllox/-</sup>; Emx1-Cre* ( $n=13$ ) used for the  
979 long-term fear conditioning (Welch's t-test,  $P=0.8999$ ). The post 24 hr fear conditioning represents cue  
980 fear conditioning, and is portrayed as Day 2 on the schematic diagram. The 24 hr fear conditioning (cue)  
981 was measured as the difference of the freezing time (%) before the tone (cue) on day 2 and during the  
982 tone (cue) on day 2. The 24 hr fear conditioning (cue) did not differ significantly between the control  
983 *Emx1-Cre* mice ( $n=12$ ) and *Bbs1<sup>fllox/-</sup>; Emx1-Cre* ( $n=13$ ) (Welch's t-test,  $P=0.7005$ ). The post 48 hr fear  
984 conditioning represents context fear conditioning, and is portrayed as Day 3 on the schematic diagram.  
985 The 48 hr fear conditioning was measured as the difference of the freezing time (%) just before  
986 conditioning (first three minutes of day 1) and during the context on day 3. Day 3 fear conditioning for  
987 context between the control *Emx1-Cre* mice ( $n=12$ ) and *Bbs1<sup>fllox/-</sup>; Emx1-Cre* ( $n=13$ ) differed significantly  
988 (Welch's t-test,  $P=0.0438$ , Mann-Whitney-Wilcoxon Test,  $P=0.0398$ ).  
989 control = *Bbs1<sup>+/+</sup>; Emx1-Cre* mice, BBS1 CKO = *Bbs1<sup>fllox/-</sup>; Emx1-Cre* mice, hr=hour, ns =not  
990 significant \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$

991

992



993

994 **Fig 5. *Bbs1*<sup>M390R/M390R</sup> mice have decreased hippocampal proliferation.**

995 A.) Normalized initial slope (%) recordings of field excitatory post synaptic potentials (fEPSP) in the  
996 hippocampal CA1 Schaffer-collateral pathway between 2 month male control mice (n=17, 4 mice) and  
997 *Bbs1*<sup>M390R/M390R</sup> mice (n=16, 4 mice). LTP was induced by 12 theta burst stimulation (TBS).

998 B.) The Long Term Potentiation (average of last five minutes of normalized initial slope of fEPSP) in the  
999 hippocampal CA1 Schaffer-collateral pathway between 2 month male control mice (n=17, 4 mice) and  
1000 *Bbs1*<sup>M390R/M390R</sup> mice (n=16, 4 mice) did not differ significantly (Welch's t-test, P=0.8407).

1001 C.) Schematic diagram of the BrdU injections of postnatal day 3 (P3) mice. P3 mice were IP injected with  
1002 300mg/kg BrdU, and taken down four hours later. Sac=Sacrifice

1003 D.) Inverted fluorescent microscope images of the P3 Dentate Gyrus. The sections were stained with  
1004 Bromodeoxyuridine (BrdU) and counterstained with the nuclear marker, DAPI. The yellow dotted line  
1005 outlines the dentate gyrus. The Red Bar line was 50um.


1006 E.) Schematic diagram of the BrdU procedures for postnatal day 44 (P44) mice. At P30, mice were started  
1007 on BrdU injections (2x50mg/kg) for five days. At P44, mice were taken down. Sac=Sacrifice

1008 F.) Inverted fluorescent microscope images of the P44 Dentate Gyrus. The sections were stained with  
1009 Bromodeoxyuridine (BrdU) and counterstained with the nuclear marker, DAPI. The yellow dotted line  
1010 outlines the dentate gyrus. The Red Bar line was 50um.

1011 G.) Decreased proliferation in the dentate gyrus of P3 *Bbs1*<sup>M390R/M390R</sup> mice. The natural logarithm of  
1012 BrdU+cell/mm<sup>3</sup> in the dentate gyrus between the control mice (n=4) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=4)  
1013 differed significantly (Welch's t-test, P=0.0038).

1014 H.) Decreased proliferation in the dentate gyrus of P44 *Bbs1*<sup>M390R/M390R</sup> mice. The natural logarithm of  
1015 BrdU+cell/mm<sup>3</sup> in the dentate gyrus between the control mice (n=6) and the *Bbs1*<sup>M390R/M390R</sup> mice (n=4)  
1016 differed significantly (Welch's t-test, P=0.0018).

1017 control=*Bbs1*<sup>+/+</sup>, *Bbs1*<sup>M390R/+</sup> mice, M390R=*Bbs1*<sup>M390R/M390R</sup> mice, hr=hour, ns=not significant, \* P< 0.05,  
1018 \*\* P< 0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001



1019

1020 **Fig 6. Chronic Lithium treatment rescued long-term context fear conditioning in *Bbs1*<sup>M390R/M390R</sup>**

1021 **mice.**

1022 A.) Schematic diagram of the Bromodeoxyuridine (BrdU) procedures for postnatal day 44 (P44) mice. At  
1023 P30, mice were started on Lithium water (45mM) or continued with water (vehicle). Mice were also  
1024 started on BrdU injections (2x50mg/kg) for five days. At P44, mice were taken down. Sac=Sacrifice  
1025 B.) Images of immunohistochemistry for neurogenesis of vehicle and lithium treated *Bbs1*<sup>M390R/M390R</sup> mice.  
1026 Z-stack, 20X, images of Dentate Gyrus at postnatal day 44 (P44). The tissue sections were stained with  
1027 BrdU, Doublecortin (DCX), and counterstained with the nuclear marker DAPI. The yellow dotted line  
1028 outlines the dentate gyrus. The White Bar line indicates 100micrometers.  
1029 C.) Proliferation in the dentate gyrus of P44 control and *Bbs1*<sup>M390R/M390R</sup> mice. We assessed two factors,  
1030 and found a significant interaction for genotype and treatment, and a difference in treatment and genotype  
1031 (2-way ANOVA, treatment X genotype, F (1, 20) = 6.428, P=0.0026, treatment, F (1, 20) = 1.569,  
1032 P=0.0177, genotype, F (1, 20) = 46.89, P<0.0001). A Sidak's multiple comparisons test showed a  
1033 significant difference in treatment for *Bbs1*<sup>M390R/M390R</sup> mice (n=5 Vehicle, n=6 Lithium, P=0.7875) but not  
1034 for control mice (n=8 Vehicle, n=5 Lithium, P=0.0010)  
1035 D.) Neurogenesis in the dentate gyrus of P44 control and *Bbs1*<sup>M390R/M390R</sup> mice. We assessed two factors,  
1036 and found a significant interaction between genotype and treatment, and a difference in treatment and  
1037 genotype (2-way ANOVA, treatment X genotype, F (1, 20) = 11.37, P=0.0005, treatment, F (1, 20) =  
1038 0.0368, P=0.5779, genotype, F (1, 20) = 29.54, P<0.0001). A Sidak's multiple comparisons test showed a  
1039 significant difference in treatment for *Bbs1*<sup>M390R/M390R</sup> mice (n=5 Vehicle, n=6 Lithium, P=0.0006) but not  
1040 for control mice (n=8 Vehicle, n=5 Lithium, P=0.3301).  
1041 E.) Timeline of LiCl treatment. At 4-5 weeks of age, mice were treated with LiCl (45mmol) water or  
1042 continued on water (vehicle). After two weeks of treatment, mice were tested on a 3 day fear conditioning  
1043 set up. Day 1 was the training (acquisition phase) for fear conditioning. The second day was testing for  
1044 cue fear conditioning. The third day was testing for context fear conditioning.  
1045 F.) Day 1 fear conditioning acquisition between the vehicle treated control mice (n=13) and  
1046 *Bbs1*<sup>M390R/M390R</sup> (45mmol) treated mice (n=10), and lithium treated control mice (n=9) and *Bbs1*<sup>M390R/M390R</sup>  
1047 (45mmol) treated mice (n=11). Graph was presented without standard error. We found a significant

1048 difference in Treatment, Genotype, and Time (3-way ANOVA, Time x Genotype x Treatment, F (13,  
1049 560) = 0.2572, P=0.9963; Genotype x Treatment, F (1, 560) = 0.4214, P=0.5165; Time x Treatment, F  
1050 (13, 560) = 1.338, P=0.1860; Time x Genotype, F (13, 560) = 0.5960, P=0.8582; Treatment, F (1, 560) =  
1051 5.475, P=0.0196; Genotype, F (1, 560) = 39.48, P<0.0001; Time, F (13, 560) = 157.3, P<0.0001). The  
1052 thick lines above the curve indicate when the sound cue was given, and the thick lines below the curve  
1053 indicate when the shock was given.

1054 G.) The immediate fear conditioning indicates training to the day 1 fear conditioning. The immediate fear  
1055 conditioning was measured as the freezing time (%) increase of the freezing time (%) just after  
1056 conditioning (last minute) to the freezing time (%) just before conditioning (first three minutes). The  
1057 immediate fear conditioning was not significantly different between the control mice given vehicle (n=13)  
1058 and control mice given LiCl water (n=10) (Welch's t-test, P=0.0689) and did not significantly differ  
1059 between the *Bbs1*<sup>M390R/M390R</sup> mice given vehicle (n=10) and *Bbs1*<sup>M390R/M390R</sup> mice given LiCl water  
1060 (45mmol) (n=11) (Welch's t-test, P=0.2834).

1061 The post 24 hr fear conditioning represents the cue fear conditioning. The 24 hr fear conditioning (cue)  
1062 was measured as the freezing time (%) increase of the freezing time (%) during the tone (cue, day 2) to  
1063 the freezing time (%) before the tone (cue, day 2). The 24 hr fear conditioning (cue) was not significantly  
1064 different between the control mice given vehicle (n=13) and control mice given LiCl water (n=10)  
1065 (Welch's t-test, P=0.7483) and was not significantly different between the *Bbs1*<sup>M390R/M390R</sup> mice given  
1066 vehicle (n=10) and *Bbs1*<sup>M390R/M390R</sup> mice given LiCl water (45mmol) (n=11) (Welch's t-test, P=0.3625).

1067 The post 48 hr fear conditioning represents the context fear conditioning. The 48 hr fear conditioning was  
1068 measured as the freezing time (%) increase of the freezing time (%) during the context on day 3 to the  
1069 freezing time (%) just before conditioning (first three minutes of day 1). Day 3 fear conditioning for  
1070 context was not significantly different between the control mice given vehicle (n=13) and control mice  
1071 given LiCl water (n=10) (Welch's t-test with Bonferroni correction, P=0.9285) but was significantly  
1072 different between the *Bbs1*<sup>M390R/M390R</sup> mice given vehicle (n=10) and *Bbs1*<sup>M390R/M390R</sup> mice given LiCl water  
1073 (45mmol) (n=11) (Welch's t-test, P=0.0235).

1074 control=*Bbs1*<sup>+/+</sup>, *Bbs1*<sup>M390R/+</sup> mice, M390R=*Bbs1*<sup>M390R/M390R</sup> mice, hr=hour, ns=not significant, \* P< 0.05,

1075 \*\* P< 0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001

1076